Bajaj Healthcare Limited
NSE: BAJAJHCARE · Pharmaceuticals · sector
₹307.45NSE close 2026-10-26
Key numbers
Market cap₹1,035 cr
Price₹307.45
52w high / low₹489 / ₹272
P/E50.7xSector median 27.9x
P/B1.9xSector median 2.9x
Book value₹165.5
Dividend yield0.31%Sector median 0.48%
ROE4.0%Sector median 11.7%
ROCE6.9%Sector median 12.3%
OPM12.2%Sector median 14.0%
Debt / equity0.48xSector median 0.16x
EV/EBITDA16.1xSector median 18.6x
Interest cover2.4x
Current ratio1.76x
Sales growth 3y-3.2%Sector median +9.6%
Profit growth 3y-28.4%Sector median +13.3%
PEG–
Last 12 months to Sep 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹38 cr vs borrowings ₹233 cr (FY26): borrowings are higher by ₹195 cr.
- Operating profit covered interest 2.4x in the last 12 months.
- Promoter holding fell by 0.60 percentage points in a year, to 58.59% (2026-09-30).
- Operating cash flow was below net profit in 3 of the last 5 years (FY25, FY23, FY22).
- Net loss in 1 of the last 8 quarters.
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- Other income was 31% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹307.45 on 2026-10-26: -37.1% from the 52-week high, +12.9% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹712.20 · low ₹274.95
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 123 | 154 | 149 | 148 | 161 | 153 | 166 | 176 |
| EBITDA | 22 | 12 | 25 | 27 | 31 | -11 | 29 | 31 |
| OPM % | 17.6% | 7.6% | 16.5% | 18.2% | 19.0% | -6.9% | 17.4% | 17.7% |
| Other income | 2 | 14 | 1 | 2 | 2 | 3 | 1 | 1 |
| Net profit | 12 | 11 | 12 | 11 | 16 | -23 | 14 | 14 |
| EPS (₹) | 3.65 | 3.54 | 3.74 | 3.53 | 4.96 | -7.16 | 4.07 | 4.19 |
| Revenue YoY | +31.3% | -0.9% | +11.3% | +18.9% | ||||
| Profit YoY | +33.7% | -304.4% | +15.8% | +26.8% |
Standalone figures where filed. Latest quarter Sep 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 680 | 673 | 473 | 543 | 611 | 656 |
| EBITDA | 118 | 107 | 32 | 82 | 72 | 80 |
| Net profit | 71 | 43 | -84 | 40 | 16 | 21 |
| EPS (₹) | 25.87 | 15.59 | -30.36 | 13.29 | 4.98 | 6.06 |
| Revenue growth | -1.0% | -29.7% | +14.6% | +12.6% | +14.2% | |
| Profit growth | -39.7% | -294.8% | – | -60.1% | -55.0% | |
| Dividend / share (₹) | – | 1.50 | 1.00 | 1.00 | 1.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -3.2% | – | +14.2% |
| Net profit | -28.4% | – | -55.0% |
| EPS | -31.6% | – | – |
| Share price | – | -7.4% (2y) | -28.7% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 368 | 278 | 466 | 533 |
| Borrowings | – | 414 | 332 | 223 | 233 |
| Cash & equivalents | – | 18 | 3 | 4 | 38 |
| Total assets | – | 901 | 765 | 833 | 923 |
| Fixed assets | – | 366 | 252 | 237 | 247 |
| Capital work in progress | – | 22 | 5 | 3 | 8 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 227 | 180 | 252 | 234 |
| Inventory | – | 209 | 144 | 162 | 216 |
| Payables | – | 85 | 89 | 95 | 115 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 1 | -22 | 92 | 22 | 58 |
| Cash from investing | -75 | -93 | -11 | -15 | -48 |
| Cash from financing | 62 | 132 | -97 | -6 | 24 |
| Capex | 74 | 94 | 30 | 12 | 43 |
| Free cash flow | -74 | -116 | 62 | 10 | 15 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 11.7% | -30.1% | 8.5% | 3.0% |
| ROCE % | – | 10.4% | 2.1% | 10.7% | 6.7% |
| Debtor days | – | 123 | 139 | 169 | 140 |
| Inventory days | – | 155 | 206 | 206 | 249 |
| Payable days | – | 63 | 128 | 122 | 133 |
| Cash conversion cycle (days) | – | 215 | 217 | 253 | 256 |
| Working capital days | – | 40 | 23 | 143 | 149 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 58.59% |
| FIIs | 2.09% |
| DIIs | 1.96% |
| of which Mutual funds | 1.69% |
| Public (non-institutions) | 37.36% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 59.19% | 59.19% | 59.19% | 59.19% | 58.29% | 58.29% | 58.59% | 58.59% |
| Promoter group | % |
|---|---|
| Sajankumar Rameshwarlal Bajaj | 36.61% |
| Anil Champalal Jain | 6.05% |
| Namrata Bajaj | 4.85% |
| Nihita Bajaj Kumar | 4.81% |
| Babita Sajankumar Bajaj | 4.47% |
| Padma Anil Jain | 0.90% |
| Bajaj Health and Nutritions LLP | 0.71% |
| Bansal Pharma Limited | 0.18% |
| SKR Bajaj HUF | 0.00% |
| Public holders above 1% | % |
|---|---|
| Deepak Ramanlal Joshi | 2.32% |
| HDFC Mutual Fund - HDFC Pharma and Healthcare Fund | 1.69% |
40,754 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| BAJAJHCARE | ₹1,035 cr | 50.7x | 1.9x | 4.0% | 6.9% | 12.2% | -3.2% | 0.31% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-11 | Dividend | Dividend - Rs 1.50 Per Share |
| 2025-09-19 | Dividend | Dividend - Re 1 Per Share |
| 2024-09-23 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
| 2023-09-22 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
| 2022-09-22 | Dividend | Annual General Meeting/Dividend - Rs 1.50 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacture of Pharmaceuticals: Manufacturing & Sale of branded Pharmaceutical Products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | BAJAJHCARE |
| BSE code | 539872 |
| ISIN | INE411U01027 |
| Face value | ₹5.0 |
| Incorporated | 1993-07-15 |
| Website | www.bajajhealth.com |
| Plants (India / abroad) | 6 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.